Cancer Genetics & Genomics Laboratory and Centre for Clinical Genomics
I completed my fellowship training at the Massachusetts General Hospital (MGH) under the supervision of Drs. David Louis and John Iafrate which resulted in a key publication on the mechanism of treatment failure in glioblastoma. Also, ongoing active collaboration with MGH has resulted in additional publications in advanced diagnostics and precision medicine. I am also a contributor to several chapters of the 2016 and 2020 WHO Classification of Tumours of the Central Nervous System, edited by Dr Louis. Key local collaborators include Dr Marco Marra, who is also my mentor and with whom I have published 39 papers in the past 10 years. We are actively collaborating on elucidating the molecular pathogenesis of glioma, particularly of CIC in oligodendroglioma. In 2012, we had discovered recurrent mutations in this gene in a majority of 1p19q- codeleted, IDH mutated oligodendroglioma. This result was later confirmed in multiple other studies including the TCGA Low Grade Glioma project. I am also collaborating with Dr Marra in the Personalized OncoGenomics (POG) program of which I am leading the pathology effort which is also branching out to involve large scale epigenomics and proteomic investigations. Results were correlated and validated against whole genome data in each POG case. My qualification as a board- certified neuropathologist with postdoctoral training in molecular experimental neuro-oncology and fellowship training in molecular genetic pathology allows me to contribute in a meaningful way to this grant application. My role as medical director of the Cancer Genetics & Genomics Laboratory and Centre for Clinical Genomics gives me the opportunity to implement province- wide strategy in cancer molecular testing which is one of the key driver in clinical decision in the era of precision oncology. This project presents a unique opportunity to explore the integration of genomic- based interrogation in pathology and to leverage existing “glass- based” assets to extend the utility, clinical impact, and cost- effectiveness of the traditional pathology workflow.